Rothwell Investment Advisors, LLC’s Definium Therapeutics DFTX Stock Holding History

Rothwell Investment Advisors, LLC’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.52K	Buy	+40	New	+$1.69K	﹤0.01%	1057

Other funds holding DFTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Rothwell Investment Advisors, LLC's DFTX Position: Q3 2026 in Review

Rothwell Investment Advisors, LLC opened a new position in Definium Therapeutics (DFTX) in Q3 2026: 40 shares worth $1.52K. The stake represents ﹤0.01% of the portfolio and ranks #1057 among its holdings.

125 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

Rothwell Investment Advisors, LLC held 40 shares of Definium Therapeutics worth $1.52K as of Q3 2026.
Definium Therapeutics was a new Rothwell Investment Advisors, LLC position in Q3 2026.
Definium Therapeutics made up ﹤0.01% of Rothwell Investment Advisors, LLC's portfolio in Q3 2026, its #1057 holding.
125 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Rothwell Investment Advisors, LLC's 13F filing for Q3 2026, filed 6 Nov 2026.